Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corin USA takes control of orthopaedics venture:

This article was originally published in Clinica

Executive Summary

Biodynamics has sold its 51% share in Corin Orthopedics Products to Corin USA, a wholly-owned subsidiary of Corin Medical (UK), for $450,000 cash. Corin USA now owns 100% of the orthopaedics venture. Biodynamics has agreed to provide Corin with accounting and management services for three years. As a result of the transaction, Biodynamics expects to report a $150,000 gain in the fourth quarter. The proceeds from the sale will be used to develop Biodynamics' tissue recovery business in the US. The company has just resumed shipment of its dura mater (see Clinica No 669/70, page 23 ).

You may also be interested in...



US FDA Commissioner Hahn’s Star Turn: Baptism By Fire Turns Perilous

Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?

Keeping Track: US FDA Okays BMS’ Zeposia In MS, Nixes Lilly/BI’s Empagliflozin For Type 1 Diabetes

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.

Topics

UsernamePublicRestriction

Register

MT093051

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel